Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026

Bausch Health (NYSE: BHC; TSX: BHC) and its Salix business will present research on severe alcohol-associated hepatitis at The Liver Meeting 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Bausch Health (NYSE: BHC; TSX: BHC) and its Salix business will present research on severe alcohol-associated hepatitis at The Liver Meeting 2026.

The meeting runs November 5–9 in Denver, Colorado. The study evaluated 1,630 adults in the United States hospitalized with severe alcohol-associated hepatitis, a liver condition associated with alcohol use. Estimated overall survival at 12 months was 62.0%. Rehospitalization occurred in 31.4% of patients within 30 days of discharge and was estimated at 69.1% by 12 months. The estimated liver transplantation rate at 12 months was 8.5%.

Key Figures

Study cohort: 1,630 adults Overall survival: 62.0% Rehospitalization: 31.4% +2 more

Study cohort: 1,630 adults; United States patients hospitalized with severe alcohol-associated hepatitis
Overall survival: 62.0%; Estimated at 12 months
Rehospitalization: 31.4%; Within 30 days of discharge
Rehospitalization: 69.1%; Estimated by 12 months
Liver transplantation rate: 8.5%; Estimated at 12 months

Key Terms

severe alcohol-associated hepatitis, overall survival

2 terms

severe alcohol-associated hepatitis medical

"patients hospitalized with severe alcohol-associated hepatitis"

An acute inflammatory liver condition caused by recent heavy alcohol use that produces jaundice and impaired liver function; 'severe' denotes cases with a high short-term risk of death based on established prognostic scores (commonly Maddrey’s discriminant function ≥32 or a high MELD score). Typical clinical features include recent onset of jaundice within weeks, elevated bilirubin, an AST-to-ALT ratio often >1.5 with modest transaminase elevations, and systemic signs of liver dysfunction. Diagnosis rests on the clinical history and laboratory pattern, requires exclusion of other causes of acute liver injury, and sometimes liver biopsy when the diagnosis is unclear.

overall survival medical

"Estimated overall survival at 12 months was 62.0%."

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/06/2026 - 07:00 AM EST

LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting^® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with severe alcohol-associated hepatitis (AH).

The study, "Clinical Burden and Outcomes in a Large Real-World Cohort of Patients Hospitalized with Severe Alcohol-Associated Hepatitis," evaluated 1,630 adults in the United States. Estimated overall survival at 12 months was 62.0%. Rehospitalization occurred in 31.4% of patients within 30 days of discharge and was estimated at 69.1% by 12 months; the estimated liver transplantation rate at 12 months was 8.5%¹.

This study underscores the growing burden of liver disease and the need for improved management strategies and effective therapies for severe AH.

"The findings of this study highlight the substantial burden of advanced liver disease and the urgent unmet need facing patients hospitalized with severe alcohol-associated hepatitis," said Jonathan Sadeh, M.D., M.Sc., Executive Vice President, Chief Medical Officer and Head of R&D, Bausch Health. "Generating real-world evidence is essential to better understanding patients' needs and informing research priorities as we work toward improving outcomes for people living with serious liver disease."

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetic, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 35 years. For more information about Salix, visit www.Salix.com and connect with us on LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

References

Jesudian A, Voegel A, Gagnon-Sanschagrin P, et al. Clinical burden and outcomes in a large real-world cohort of patients hospitalized with severe alcohol-associated hepatitis. Poster 3154 presented at: The Liver Meeting® 2026; November 5–9, 2026; Denver, CO

BHC-PRODUCTS

Investor Contact:	Media Contacts:
Garen Sarafian	Alexis Navratil
ir@bauschhealth.com	corporate.communications@bauschhealth.com
877-281-6642 (toll-free)	(848) 264-0934